Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803995 | 0.80 | GNAI3 (0.36) | HRH4HRH3HRH2GNAI3GNAO1 | |
| SCHEMBL19709243 | 0.78 | KCNH2 (0.37) | KCNH2GBA1 | |
| SCHEMBL7893718 | 0.77 | GNAI3 (0.53) | HRH4HRH3HRH2KCNH2SIGMAR1 | |
| SCHEMBL13912964 | 0.76 | RAD52 (0.41) | SIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL12156771 | 0.76 | RAD52 (0.37) | GNAI3GNAO1GNAI1 | |
| SCHEMBL4661086 | 0.75 | — | — | |
| SCHEMBL3645463 | 0.74 | RAD52 (0.44) | HRH3SIGMAR1 | |
| SCHEMBL22030925 | 0.74 | — | — | |
| SCHEMBL23407882 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL20912586 | 0.73 | GNAI3 (0.44) | HRH4HRH2KCNH2SIGMAR1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | HRH4 3383/4885HRH3 3537/4885HRH2 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.